n-acetylglucopyranosylamine has been researched along with olmesartan in 1 studies
| Studies (n-acetylglucopyranosylamine) | Trials (n-acetylglucopyranosylamine) | Recent Studies (post-2010) (n-acetylglucopyranosylamine) | Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) |
|---|---|---|---|---|---|
| 17 | 0 | 3 | 841 | 185 | 554 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, K; Horino, T; Inoue, K; Kagawa, T; Matsumoto, R; Morita, T; Takao, T | 1 |
1 other study(ies) available for n-acetylglucopyranosylamine and olmesartan
| Article | Year |
|---|---|
Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Apoptosis; Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial Cells; Glucosamine; Humans; Imidazoles; Kidney Tubules, Proximal; L-Lactate Dehydrogenase; NADPH Oxidases; Pyridines; Receptor, Angiotensin, Type 2; Receptors, Tumor Necrosis Factor, Type I; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2008 |